The Efficacy of Pramipexole, a Dopamine Receptor Agonist, as an Adjunctive Treatment in Treatment-Resistant Depression: An Open-Label Trial

Table 1

Demographic characteristics and clinical variables at baseline.

Variable	Value
Diagnosis: bipolar II disorder/major depressive disorder
Bipolar II disorder, n	5
Major depressive disorder, n	12
Stage of treatment-resistant depression
Stage II	4
Stage III	13
Age, years: mean (SD)	36.2 ± 9.2
Gender: female, n (%)	10 (58.8)
Experience of hospitalizations: Yes, n (%)	6 (35.3)
History of suicidal attempt: Yes, n (%)	4 (23.5)
Family history of psychiatric disorder within first-degree relatives: Yes, n (%)	6 (35.3)
Age at onset, years: mean (SD)	28.1 ± 7.6
Age at first contact to psychiatric service, years: mean (SD)	30.2 ± 8.1
HDRS-21 total score: mean (SD)	19.4 ± 3.8
CGI-S score: median (range)	5 (3–6)

HDRS-21: 21-item version of the Hamilton Depression Rating Scale.